Secukinumab is a monoclonal antibody that targets IL-17A. It has been registered and approved by FDA for treating patients with moderate to severe psoriasis. Promising results have also been obtained in treating psoriatic arthritis and ankylosing spondylitis.

The project submitted for assessment presents properly constructed assumptions. It is to recruit a relatively large population of 2,500 psoriatic patients (including 1,250 treated with secukinumab).

The treatment assessment parameters proposed by the Authors are likely to extend knowledge on treatment effectiveness, which in the context of the follow-up period might contribute to identification of patients in whom this type of treatment does not bring in the expected outcomes. A reliable register and verification of adverse events and effects will constitute a very valuable source of knowledge for clinicians.

Some doubts may only be evoked by the modest set of exclusion criteria (e.g. no information on a heart attack or a stroke).

The long follow-up period, the number of patients and the comparison of therapeutic effects depending on the treatment administered, indicate that there is a possibility of obtaining valuable clinical information on biological treatment in psoriatic patients.

If encoded patient data, including treatment used, are analysed by a centre independent of the manufacturer, the study will be more objective.

Summary:

approval
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Unable to assess

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I have no conflict of interest

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal